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Abstract
Purpose Triacetone triperoxide (TATP) is a volatile but powerful explosive that appeals to terrorists due to its ease of syn-
thesis from household items. For this reason, bomb squad, canine (K9) units, and scientists must work with this material to 
mitigate this threat. However, no information on the metabolism of TATP is available.
Methods In vitro experiments using human liver microsomes and recombinant enzymes were performed on TATP and TATP-
OH for metabolite identification and enzyme phenotyping. Enzyme kinetics for TATP hydroxylation were also investigated. 
Urine from laboratory personnel collected before and after working with TATP was analyzed for TATP and its metabolites.
Results While experiments with flavin monooxygenases were inconclusive, those with recombinant cytochrome P450s 
(CYPs) strongly suggested that CYP2B6 was the principle enzyme responsible for TATP hydroxylation. TATP-O-glucuronide 
was also identified and incubations with recombinant uridine diphosphoglucuronosyltransferases (UGTs) indicated that 
UGT2B7 catalyzes this reaction. Michaelis–Menten kinetics were determined for TATP hydroxylation, with Km = 1.4 µM 
and Vmax = 8.7 nmol/min/nmol  CYP2B6. TATP-O-glucuronide was present in the urine of all three volunteers after being 
exposed to TATP vapors showing good in vivo correlation to in vitro data. TATP and TATP-OH were not observed.
Conclusions Since scientists working to characterize and detect TATP to prevent terrorist attacks are constantly exposed 
to this volatile compound, attention should be paid to its metabolism. This paper is the first to elucidate some exposure, 
metabolism and excretion of TATP in humans and to identify a marker of TATP exposure, TATP-O-glucuronide in urine.
Keywords Triacetone triperoxide (TATP) · Terrorists · Human in vitro and in vivo metabolism for TATP exposure · TATP-
O-glucuronide · CYP2B6 hydroxylation · UGT2B7 glucuronidation
Introduction
Triacetone triperoxide (3,3,6,6,9,9-hexamethyl-1,2,4,5,7,8-
hexoxonane, TATP) is a homemade explosive, easily synthe-
sized from household items [1]. For this reason, TATP has 
often been used by terrorists [2, 3], necessitating its research 
by bomb squad, canine (K9) units, and scientists [4]. In addi-
tion to being extremely hazardous, this peroxide explosive 
is highly volatile, with partial pressure of 4–7 Pa at 20 ℃ 
[5, 6]. Personnel exposed to TATP will most likely absorb it 
through inhalation and/or dermal absorption. However, no 
information on the human absorption, distribution, metabo-
lism, excretion and toxicity (ADMET) of TATP is available. 
Therefore, this paper will investigate the in vitro metabolism 
of TATP and the in vivo excretion through urine analysis.
The toxicity of most military explosives has been well 
characterized [7]. The biotransformation of trinitrotoluene, 
for example, has been thoroughly investigated. It is metabo-
lized by cytochrome P450 (CYP) reductase, forming nitroso 
intermediates, and yielding 4-hydroxylamino-2,6-dinitrotol-
uene, 4-amino-2,6-dinitrotoluene and 2-amino-4,6-dinitro-
toluene. These primary metabolites are further reduced by 
CYP to 2,4-diamino-6-nitrotoluene and 2,6-diamino-4-nitro-
toluene [8, 9]. In vivo studies of Chinese ammunition factory 
workers found metabolites, such as 4-amino-2,6-dinitrotol-
uene and 2-amino-4,6-dinitrotoluene, in urine and bound 
to the hemoglobin in blood [9, 10]. TATP has been studied 
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for almost two decades, but its metabolism and toxicity are 
still unknown. TATP characterization is problematic since 
it is an extremely sensitive explosive, difficult to handle and, 
due to its high volatility, difficult to concentrate in biological 
samples [5].
Most xenobiotics are metabolized by CYP which is a fam-
ily of heme-containing enzymes found in all tissues, particu-
larly the liver endoplasmic reticulum (microsomes). CYPs 
catalyze phase I oxidative reactions (among others) in the 
presence of oxygen and a reducing agent (usually reduced 
nicotinamide adenine dinucleotide phosphate, NADPH). 
NADPH provides electrons to the CYP heme via CYP 
reductase. This oxidation generally produces more polar 
metabolites that are either excreted in the urine or undergo 
phase II biotransformation, further increasing their hydro-
philicity [11]. One of the most common phase II reactions 
is glucuronidation, which is catalyzed by uridine diphos-
phoglucuronosyltransferase (UGT) in the presence of the 
cofactor uridine diphosphoglucuronic acid (UDPGA). In this 
reaction, glucuronic acid is conjugated onto an electron-rich 
nucleophilic heteroatom, frequently added to the substrate 
by phase I metabolism. Glucuronide metabolites increase 
the topological polar surface area (TPSA) and reduce the 
partition coefficient (LogP) of xenobiotics to be ionized at 
physiological pH, thus, increasing the aqueous solubility of 
the compound for excretion [11].
TATP is a cyclic peroxide, a motif shared with the antima-
larial drug, artemisinin. The endoperoxide functionality of 
artemisinin is thought to be crucial for its antimalarial activ-
ity [12]. In the presence of ferrous ions, artemisinin under-
goes homolytic peroxide cleavage to yield an oxygen radical 
that may be lethal to malaria parasite, Plasmodium falci-
parum. Biotransformation studies indicate that artemisinin 
is primarily metabolized by CYP2B6 to deoxyartemisinin, 
deoxydihydroartemisinin, dihydroartemisinin and ‘crystal-7’ 
[13, 14]. Similarly, we have previously shown that TATP is 
metabolized in vitro by canine CYP2B11, another CYP2B 
subfamily enzyme [15]. Artemisinin is further metabolized 
by glucuronidation, particularly by UGT1A9 and UGT2B7, 
to dihydroartemisinin-glucuronide, the principal metabolite 
found in urine, suggesting endoperoxides, like TATP, may 
be glucuronidated and excreted in urine [16].
Laboratory personnel who work on synthesizing, char-
acterizing and detecting TATP are inevitably exposed to 
this volatile compound. Even the small-sized samples that 
they work with can result in buildup of TATP in a confined 
space. Furthermore, bomb-sniffing dogs and their handlers 
are purposely exposed to these vapors for the sake of train-
ing. Our previous study revealed TATP metabolism in dog 
liver microsomes (DLM) [15]. Now we evaluate its in vitro 
biotransformation in human liver microsomes (HLM) and 
recombinant enzymes, identifying phase I and phase II 
metabolites, estimating enzyme kinetics and also detecting 
urinary in vivo metabolites excreted from scientists exposed 
to TATP in their work environment.
Materials and methods
Chemicals
Optima HPLC grade methanol, Optima HPLC grade water, 
Optima HPLC grade acetonitrile, American Chemical Soci-
ety (ACS) grade acetone, ACS grade methanol, ACS grade 
pentane, hydrochloric acid, ammonium acetate, dipotas-
sium phosphate, monopotassium phosphate, magnesium 
chloride  (MgCl2) and reduced glutathione (GSH) were 
purchased from Fisher Chemical (Fair Lawn, NJ, USA); 
NADPH, 1-aminobenzotriazole, methimazole, 1-naphthol 
and hydroxyacetone from Acros Organics (Morris Plain, 
NJ, USA); UDPGA, saccharolactone and 2,4-dichlorophe-
noxyacetic acid from Sigma-Aldrich (St. Louis, MO, USA); 
bupropion, benzydamine and alamethicin from Alfa Aesar 
(Ward Hill, MA, USA); oxcarbazepine from European 
Pharmacopoeia Reference Standard (Strasbourg, France); 
ticlopidine from Tokyo Chemical Industry (Tokyo, Japan); 
hydroxybupropion from Cerilliant Corporation (Round 
Rock, Texas, USA); deuterated acetone (acetone-d6) from 
Cambridge Isotope Labs (Cambridge, MA, USA); hydro-
gen peroxide (50%) from Univar (Redmond, WA, USA); 
HLM, rat liver microsomes (RLM), DLM and human lung 
microsomes (HLungM) from Sekisui XenoTech (Kansas 
City, KS, USA); human recombinant CYP (rCYP) bacto-
somes expressed in Escherichia coli (E. coli) from Cypex 
(Dundee, Scotland); human recombinant flavin monooxy-
genase (rFMO) supersomes and human recombinant UGT 
(rUGT) supersomes expressed in insect cells from Corning 
(Woburn, MA, USA).
TATP, deuterated TATP (TATP‑d18) and hydroxy‑TATP 
(TATP‑OH) synthesis
TATP was synthesized following the literature methods 
using hydrochloric acid as the catalyst [1]. TATP was puri-
fied by recrystallization, first with methanol/water (80:20, 
v/v) and then with pentane. TATP-d18 was synthesized as 
above using acetone-d6. TATP-OH was synthesized as above 
using hydrogen peroxide (50 wt%)/acetone/hydroxyacetone 
(2:1:1, v/v/v) [15]. TATP-OH was purified using a Combi-
Flash RF + system with an attached PurIon S MS system 
(Teledyne Isco, Lincoln, NE, USA), followed by two cycles 
of drying and reconstituting in solvent to sublime away the 
TATP. Separation was performed using a C-18 cartridge 
combined with a liquid chromatograph flow of 18 mL/min 
with 10% methanol (A) and 90% aqueous 10 mM ammo-
nium acetate (B) for 1 min, before ramping to 35%A/65%B 
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over 1 min, followed by another ramp to 95%A/5%B over 
the next 1 min, holding for 2 min, before a 30 s transition to 
initial conditions, with a hold of 2 min [15].
Instrumental analyses 
Metabolite identification was performed by high‐perfor-
mance liquid chromatography coupled to Thermo Scien-
tific Exactive or Thermo Scientific LTQ Orbitrap XL high-
resolution mass spectrometers (HPLC–HRMS) (Thermo 
Fisher Scientific, Waltham, MA, USA). A CTC Analytics 
PAL autosampler (CTC Analytics, Zwingen, Switzerland) 
was used for LC injections, solvent delivery was performed 
using a Thermo Scientific Accela 1200 quaternary pump, 
and data collection/analysis was done using Xcalibur soft-
ware (Thermo Scientific, version 2.1).
Metabolite quantification was performed by high‐perfor-
mance liquid chromatography coupled to AB Sciex Q-Trap 
5500 triple quadrupole mass spectrometer (HPLC–MS/MS) 
(AB Sciex, Toronto, Canada). A CTC Analytics PAL autosa-
mpler was used for LC injections, solvent delivery was per-
formed using a Thermo Scientific Accela 1200 quaternary 
pump and data collection/analysis was done with Analyst 
software (AB Sciex, version 1.6.2).
The HPLC method for all TATP derivatives was as fol-
lows: sample of 40 µL (Exactive and LTQ Orbitrap XL) 
or 20 µL (Q-Trap 5500) in acetonitrile/water (50:50, v/v) 
was injected into LC flow at 250 µL/min of 10%A/90%B 
for introduction onto a Thermo Syncronis C18 column 
(50 × 2.1 mm i.d., particle size 5 µm). Initial conditions 
were held for 1 min before ramping to 35%A/65%B over 
1 min, followed by another ramp to 95%A/5%B over the 
next 1 min. This ratio was held for 2 min before reverting to 
initial conditions over 30 s, which was held for additional 
2 min. The Exactive MS tune conditions for atmospheric 
pressure chemical ionization (APCI) in positive mode were 
as follows:  N2 sheath gas flow rate, 30 arbitrary units (AU); 
 N2 auxiliary gas flow rate, 30 AU; discharge current, 6 µA; 
capillary temperature, 220 ℃; capillary voltage, 25 V; tube 
lens voltage, 40 V; skimmer voltage, 14 V; and vaporizer 
temperature, 220 ℃. The Exactive MS tune conditions for 
electrospray ionization (ESI) in negative mode were as fol-
lows:  N2 sheath gas flow rate, 30 AU;  N2 auxiliary gas flow 
rate, 15 AU; spray voltage, − 3.4 kV; capillary tempera-
ture, 275 ℃; capillary voltage, − 35 V; tube lens voltage, 
− 150 V; and skimmer voltage, − 22 V. The LTQ Orbitrap 
XL MS tune conditions for ESI−, used for TATP-O-glucu-
ronide verification, were as follows:  N2 sheath gas flow rate, 
30 AU;  N2 auxiliary gas flow rate, 15 AU; spray voltage, 
− 4 kV; capillary temperature, 275 °C; capillary voltage, 
− 15 V; and tube lens voltage, − 84 V. The single-reaction 
monitoring settings were as follows: m/z 413.13 with iso-
lation width m/z 1.7, activated by higher-energy collision 
dissociation at 35 eV. The Q-trap 5500 MS tune and mul-
tiple reaction monitoring (MRM) conditions are shown in 
Table 1. TATP and TATP-OH quantification was done as the 
area ratio to TATP-d18 (internal standard, IS) using a stand-
ard curve ranging 10–20,000 ng/mL and 10–500 (Fig. S1) or 
500–8,000 ng/mL, respectively. TATP-O-glucuronide rela-
tive quantification was done as the area ratio to 2,4-dichlo-
rophenoxyacetic acid (IS).
The HPLC method for bupropion, hydroxybupropion, 
benzydamine, benzydamine N-oxide, and oxcarbazepine 
(IS) was as follow: sample of 10 μL in acetonitrile/water 
(50:50, v/v) was injected into LC flow at 250 μL/min with 
30%A/70%B for introduction onto a Thermo Scientific 
Acclaim Polar Advantage II C18 column (50 × 2.1 mm i.d., 
particle size 3 µm). Initial conditions were held for 1 min 
before instant increase to 95%A/5%B, held for 2.5 min, and 
then reversed to initial conditions over 30 s, with a hold of 
1 min for the bupropion, hydroxybupropion and oxcarbaz-
epine method or with a hold of 3 min for the benzydamine, 
benzydamine N-oxide and oxcarbazepine method.
Metabolite identification
All incubations were performed in triplicate in a Thermo 
Scientific Digital Heating Shaking Drybath set to body tem-
perature 37 ℃ and 800 rpm. An incubation mixture contain-
ing phosphate buffer (pH 7.4),  MgCl2 [17], and NADPH 
(CYP cofactor [11]) was prepared so that at a final volume 
of 1 mL, their concentrations were 10, 2 and 1 mM, respec-
tively. When the incubation times were relatively long 
(greater than 15 min), it was thought necessary to use closed 
vessels to avoid loss of the volatile TATP or TATP-OH; as a 
result, prior to incubation, oxygen gas was bubbled through 
the buffer to ensure ample oxygen availability [15]. To this 
mixture, microsomes or recombinant enzymes were added 
and equilibrated for 3 min before the reaction was initiated 
by adding the substrate. Substrates included TATP in ace-
tonitrile, TATP-OH in methanol, and bupropion and benzy-
damine in water. Organic solvents can disrupt metabolism, 
but the catalytic activity of most CYP enzymes is unaffected 
by less than 1% acetonitrile or methanol [18]. At the end 
point, an aliquot was transferred to a vial containing equal 
volume of ice-cold acetonitrile and immediately vortex-
mixed to quench the reaction. The sample was centrifuged 
for 5 min at 14,000 rpm, and the supernatant was analyzed 
by LC–MS.
Metabolite identification studies used microsomes (HLM, 
RLM and DLM) at protein concentrations of 1 mg/mL in 
the incubation mixture. The substrate, TATP, TATP-OH, or 
TATP-d18 (10 µg/mL) was allowed to incubate for several 
min before MS analysis. Negative controls consisted of the 








































































































































































































































































































































































































































































































































































































































































Positive control used 100 µM bupropion, a probe substrate 
for CYP2B6 [19–21].
Phase II TATP metabolism was examined by two studies. 
Metabolism by glutathione S-transferase (GST) was probed 
by equilibrating 5 mM GSH (GST cofactor [11]) for 5 min in 
the incubation mixture including HLM before the substrate 
(TATP) was added. Ticlopidine (10 µM) was the substrate 
for the GST positive control (Fig. S2) [22]. To examine 
metabolism by UGT, HLM, buffer, and alamethicin (50 µg/
mL in methanol/water) were equilibrated cold for 15 min, 
before saccharolactone (1 mg/mL, β-glucuronidase inhibitor 
[23]),  MgCl2, and NADPH were added, and the mixture was 
warmed to 37 ℃ and shaken at 800 rpm. After 3 min equili-
bration, the substrate (TATP or TATP-OH) was added, and 
in 2 min, the reaction was started by the addition of 5.5 mM 
UDPGA (UGT cofactor [11]) [24, 25]. Positive control used 
100 µM 1-naphthol, an UGT1A6 substrate (Fig. S3) [26, 27]. 
Alamethicin was employed to replace membrane transport-
ers, in allowing UGT (located in the endoplasmic reticulum 
lumen) easy access to the UDPGA cofactor [11].
Enzyme identification
TATP was incubated as described in the previous section 
with various enzyme inhibitors in HLM (1 mg/mL). TATP-
OH formation was first monitored and benchmarked against 
incubations without inhibitors. Chemical inhibitors, such 
as 1-aminobenzotriazole (1 mM) [28, 29], methimazole 
(500 µM) [30, 31], or ticlopidine (100 µM) [32, 33], were 
pre-equilibrated in the incubation mixture for 30 min prior 
to the addition of the substrate (100 µM, TATP or controls). 
TATP was also tested as a possible CYP2B6 inhibitor; TATP 
or bupropion was pre-equilibrated in the incubation mixture 
before starting the reaction with a known CYP2B6 substrate 
(bupropion) or TATP, respectively. FMO inhibition by heat 
was also tested [11, 34]. In that experiment, HLM was mixed 
with buffer and preheated at 37 or 45 ℃ for 5 min. After an 
hour, cooling on ice, the incubation procedure was resumed. 
Bupropion, a CYP2B6 substrate [19–21], and benzydamine, 
an FMO substrate [34], were used as positive and negative 
control substrates to assess CYP, FMO and CYP2B6 inhibi-
tion. Samples not preincubated with chemical inhibitors nor 
heated to 45 ℃ were used as 100% TATP-OH formation. 
Inhibition studies were quenched after 15 min incubation.
Recombinant CYP and FMO enzymes were employed to 
identify the isoform responsible for the NADPH-dependent 
metabolism. Human bactosomes expressed in E. coli were 
used for CYP isoform identification; CYP1A2, CYP2B6, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 
(100  pmol CYP/mL) were tested. Human supersomes 
expressed in insect cells were used for FMO isoform iden-
tification; FMO1, FMO3 and FMO5 (100 µg protein/mL) 
were examined. Both TATP and TATP-OH were tested as 
the substrate (10 µg/mL) in the incubation mixture with the 
recombinant enzymes. Negative control incubations were 
done in E. coli control or insect cell control. Positive control 
incubations were done in HLM (200 pmol CYP/mL), which 
contains all CYP and FMO enzymes. Recombinant enzymes 
studies were quenched after 10 min incubation.
Recombinant UGT enzymes were used to identify the 
isoform responsible for phase II metabolism. Human super-
somes expressed in insect cells were used for UGT isoform 
identification; UGT1A1, UGT1A3, UGT1A4, UGT1A6, 
UGT1A9 and UGT2B7 were examined. The incubation 
mixture was similar to the glucuronidation incubation pre-
viously described, except that saccharolactone was not added 
[35]; 500 µg protein/mL was used; and the substrate was 
10 µg/mL TATP-OH. Negative control incubations were 
done in insect cell control. Positive control incubations were 
done in HLM (1 mg protein/mL), which contained all UGT 
enzymes. Glucuronidation with recombinant enzymes was 
quenched after 2 h incubation.
Enzyme kinetics
Kinetics experiments were done to determine the affinity 
of the enzyme CYP2B6 to the substrate TATP. The human 
CYP2B6 bactosomes used contained human CYP2B6 and 
human CYP reductase coexpressed in E. coli, supplemented 
with purified human cytochrome  b5. Cytochrome P450 
reductase is responsible for the transfer of electrons from 
NADPH to CYP, a task sometimes extended to cytochrome 
 b5 [11]. The incubation mixture (1 mL) contained 10 mM 
phosphate buffer (pH 7.4), 2 mM  MgCl2, 50 nM rCYP2B6, 
1 mM NADPH, and various concentrations of 0.1 to 20 µM 
TATP. The reaction was initiated by adding TATP after a 
3 min pre-equilibration and stopped at different end points 
(up to 5 min) to determine rate of TATP hydroxylation. The 
rate of TATP hydroxylation in lungs was also investigated by 
incubating TATP (100 µM) in the incubation mixture con-
taining 1 mg/mL HLM or HLungM, instead of rCYP2B6, 
for up to 10 min.
TATP-OH metabolism by CYP2B6 was evaluated by 
incubating 10 µg/mL TATP-OH in CYP2B6 bactosomes 
according to the above procedure, with or without NADPH, 
except that the buffer was preoxygenated so that the incu-
bation could be performed in a closed vessel. Aliquots 
were removed and quenched at different time points, up to 
30 min. TATP-OH depletion by HLM was determined using 
the same procedure, except that 1 µM TATP-OH and up to 
60 min reaction times were used.
Urine analysis
Laboratory personnel testing TATP are constantly exposed 
to this volatile compound. Explosive sensitivity experiments, 
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such as drop weight impact tests, are done in a small brick-
walled room for explosivity precautions, unlike synthesis 
reactions which are performed inside a fume hood for cov-
erage protection. Also, portable explosive trace detection 
devices that are meant to be used in the field are tested as 
such, which also contribute to exposure. Urine from labora-
tory workers was tested for TATP and its metabolites after 
TATP exposure in the laboratory environment. Urine was 
collected at the beginning of the work week and 2 h after 
performing activities that could lead to high TATP exposure. 
To determine the longevity of TATP in the body, urine from 
the day following TATP exposure was also tested. The fresh 
urine was cleaned and concentrated for analysis using solid-
phase extraction. Restek RDX column (Restek, Bellefonte, 
PA, USA) was conditioned with 6 mL of methanol, followed 
by 6 mL of water, and sample introduction (20–250 mL 
urine). The sample was washed with two cycles of 3 mL 
methanol/water (50:50, v/v). Extraction was achieved with 
two cycles of 1 mL acetonitrile. Both eluents were tested by 
LC–MS, because the lipophilic TATP and TATP-OH were 
extracted with acetonitrile, but the hydrophilic TATP-O-glu-
curonide was present in the methanol/water wash.
Results
Metabolite identification
When TATP was incubated in HLM, TATP was depleted, 
and one observable product, TATP-OH, was formed over 
time (Fig. 1). Metabolism of TATP in HLM consists of 
hydroxylation at one methyl group with the peroxide bonds 
and nine-membered ring structure preserved (Fig. 2) [15]. 
Opsenica and Solaja [12] reported various monohydroxy-
lated and dihydroxylated products during microsomal 
incubations with cyclohexylidene and steroidal mixed 
tetraoxanes where the peroxide bond was also preserved. A 
Fig. 1  Triacetone triperoxide 
(TATP) biotransformation into 
hydroxy-TATP (TATP-OH) 
monitored over time in human 
liver microsomes (HLM), per-
formed in triplicate
Fig. 2  TATP metabolic pathways in HLM. CYP cytochrome P450, UGT uridine diphosphoglucuronosyltransferase
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TATP-OH standard (Fig. S4) was chemically synthesized to 
confirm the metabolite by retention time and mass-to-charge 
ratio (m/z). TATP-OH, identified as [TATP-OH + NH4]+ (m/z 
256.1391) by accurate mass spectrometry, increased in incu-
bation samples as time progressed. Attempts to confirm the 
hydroxylated metabolite with the deuterated substrate were 
unsuccessful due to the persistence of a contaminant with 
the same mass that the metabolite would have had, even in 
samples where TATP-d18 was not used as the substrate. As 
previously observed, TATP incubations in different species 
(dogs and rats) yielded the same metabolite, TATP-OH (Fig. 
S5) [15]. Other suspected metabolites, including the dihy-
droxy-species and additional oxidation of the TATP-OH to 
the aldehyde and carboxylic acid were not observed. Small 
polar molecules, such as acetone and hydrogen peroxide, the 
synthetic reagents of TATP, could not be chromatographi-
cally separated or are below the lower mass filter limit.
TATP was investigated for phase II metabolism routes 
of glutathione and glucuronide conjugation. Incubation 
in HLM with GSH produced no detectable glutathione 
metabolite conjugates, indicating that TATP is most 
likely not a substrate for microsomal GSTs (Fig. S6). 
When TATP was incubated with UDPGA, the TATP-OH 
glucuronic acid metabolite (TATP-O-glucuronide) was 
observed (Fig. 2). The m/z 432.1712 for [TATP-O-glu-
curonide + NH4]+ was observed at very low levels after 
Fig. 3  Product ion spectrum of [TATP-O-glucuronide −  H]− (m/z 413.1301), fragmented with 35 eV using electrospray ionization in negative 
mode (ESI–). Proposed structures are shown
Table 2  Average % metabolites 
formed (triplicates) in 15 min 
incubations with chemical 
inhibitors or heat
1-ABT 1-aminobenzotriazole (CYP inhibitor), CYP cytochrome P450, FMO flavin monooxygenase, HLM 
human liver microsomes, MMI methimazole (FMO inhibitor), TIC ticlopidine (CYP2B6 inhibitor) (for 




Inhibitor preincubated in HLM for 30 min HLM preheated 
for 5 min
No inhibitor 1-ABT MMI TIC TATP or BUP 37 ℃ 45 ℃
TATP-OH (%) 100 ± 5 3.6 ± 0.7 34 ± 2 4.8 ± 0.7 125 ± 21 100 ± 10 69 ± 4
BUP-OH (%) 100 ± 3 23 ± 1 62 ± 2 9.6 ± 0.4 62 ± 2 100 ± 6 99 ± 2
BZD-NO (%) 100 ± 2 97 ± 1 48 ± 1 98 ± 3 N/A 100 ± 2 44 ± 2
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2 and 3 h of incubation. When the sample was dried and 
reconstituted in low volume, the intensity of [TATP-
O-glucuronide + NH4]+ increased, but TATP and TATP-
OH were evaporated along with the solvent. TATP and 
TATP-OH are volatile, limiting their use in quantification 
experiments since sample concentration is not feasible [5]. 
However, TATP-O-glucuronide is a non-volatile TATP 
derivative that is amenable to sample preparation. For-
mation of TATP-O-glucuronide over time was monitored, 
using concentrated samples, as an intensity increase of 
m/z 432.1712 (Fig. S7). Even though TATP and TATP-
OH generally form ammonia adducts under positive ion 
APCI, the glucuronide favors negative ion mode ESI. The 
m/z 413.1301 for [TATP-O-glucuronide − H]− was easily 
seen at 1–3 h without sample concentration. The common 
fragments of glucuronic acid, m/z 175, 113, and 85, were 
observed in the fragmentation pattern of m/z 413.1301, 
confirming the presence of a glucuronic acid conjugate 
(Fig. 3) [36]. TATP-O-glucuronide was not observed in 
negative controls without UDPGA or NADPH, indicating 
that TATP-OH must be formed and then be further metab-
olized into TATP-O-glucuronide. Glucuronide conjugates 
are highly polar compounds that are easily eliminated by 
the kidney, suggesting that TATP-O-glucuronide would 
likely progress via urinary excretion [11].
Enzyme identification
TATP was only metabolized into TATP-OH in HLM in 
the presence of NADPH, indicating that the metabolism is 
NADPH-dependent. The predominant microsomal enzymes 
that require NADPH for activity are CYP and FMO [11].
The usual roles of CYP are hydroxylation of an ali-
phatic or aromatic carbons, epoxidation of double bonds, 
heteroatom oxygenation or dealkylation, oxidative group 
transfer, cleavage of esters and dehydrogenation reactions 
[11]. 1-Aminobenzotriazole is considered a general mecha-
nism-based inhibitor of CYPs, initiated by metabolism into 
benzyne, which irreversibly reacts with the CYP heme [28, 
29]. When CYP activity was inhibited by 1-aminobenzo-
triazole, TATP-OH formation was also inhibited, with only 
3.6% formed (Table 2), suggesting that CYP is involved in 
the hydroxylation of TATP. To support this evidence and to 
narrow down the CYP isoform catalyzing TATP hydroxyla-
tion, TATP was incubated with rCYPs (Fig. 4, Table S1). 
The CYPs selected for testing are responsible for the metab-
olism of 89% of common xenobiotics [37]. TATP-OH was 
not observed when TATP was incubated with CYP1A2, 
CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4. 
TATP hydroxylation was performed exclusively by CYP2B6, 
with 5.6 ± 0.3 µM TATP-OH produced in 10 min. CYP2B6 
has been found to metabolize endoperoxides by hydroxyla-
tion, as observed for TATP [13, 14]. HLM, which contains 
CYP2B6, also exhibited TATP hydroxylation (1.5 ± 0.1 µM).
Since DLM studies indicated that TATP is metabolized 
by CYP2B11 [15], it was not surprising that another CYP2B 
subfamily enzyme, CYP2B6, metabolizes TATP in humans. 
CYP2B6 metabolism of TATP was further investigated by 
incubating TATP with ticlopidine, a mechanism-based 
inhibitor of CYP2B6 [32, 33]. When CYP2B6 activity 
was inhibited by ticlopidine, TATP-OH formation was also 
inhibited by 95% (Table 2), further supporting the primary 
involvement of CYP2B6 in the metabolism of TATP. Bupro-
pion hydroxylation is catalyzed by CYP2B6; therefore, it 
was chosen as a positive control for CYP and CYP2B6 inhi-
bition tests [28]. Hydroxybupropion formation was inhibited 
Fig. 4  TATP-OH formation from TATP incubations with recombi-
nant cytochrome P450 (rCYP) and recombinant flavin monooxyge-
nase (rFMO). Experiments with rCYP or rFMO consisted of 10 µg/
mL TATP incubated with 10 mM phosphate buffer (pH 7.4), 2 mM 
 MgCl2 and 1 mM NADPH. Incubations were done in triplicate and 
quenched at 10 min
Table 3  Average % TATP-OH remaining (triplicates) after 10  min 
incubation in recombinant enzymes
rCYP recombinant cytochrome P450, rFMO recombinant flavin 
monooxygenase
Incubation matrix Percent TATP-
OH remaining
HLM 69 ± 5
rCYP control 76 ± 4
rCYP1A2 77 ± 2
rCYP2B6 60 ± 3
rCYP2C9 71 ± 8
rCYP2C19 76 ± 5
rCYP2D6 76 ± 5
rCYP2E1 73 ± 5
rCYP3A4 78 ± 6
rFMO control 69 ± 3
rFMO1 78 ± 12
rFMO3 78 ± 6
rFMO5 72 ± 7
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by 77 and 90% when incubated with 1-aminobenzotriazole 
and ticlopidine, respectively (Table 2).
FMO catalyzes oxygenation of nucleophilic heteroatoms, 
such as nitrogen, sulfur, phosphorous and selenium [34, 
38]. Although FMO involvement in the hydroxylation of 
the TATP methyl group was unlikely, it seemed prudent to 
examine this enzyme class. Addition of methimazole, an 
FMO competitive inhibitor [30, 31], caused a decrease in 
TATP-OH formation by 66% (Table 2), but this is not neces-
sarily direct inhibition of TATP metabolism by FMO since 
methimazole has been reported to reduce CYP2B6 activity 
by up to 80% [34, 39]. While this result was inconclusive 
about the FMO contributions to TATP metabolism, it could 
be considered further support for the role of CYP2B6. TATP 
was incubated with available rFMOs: FMO1, FMO3 and 
FMO5 (Fig. 4, Table S1). FMO1 is expressed in adults in the 
kidneys, and it should not contribute to the liver metabolism 
of TATP [34]; indeed, none appeared to be involved as no 
TATP-OH was produced (positive control, Fig. S8). Since 
FMO is inactivated by heat [11, 34], TATP was incubated 
in HLM pre-heated to 45 ℃ for 5 min. Table 2 compares the 
formation of TATP-OH at 37 ℃ to that at 45 ℃ and to the 
N-oxidation of the positive control, benzydamine. Although, 
there was a decrease in TATP hydroxylation, the inhibitory 
effect was not as significant as compared to the decrease in 
benzydamine N-oxidation, which is catalyzed by FMO.
TATP-OH appears to be metabolized by HLM in an 
NADPH-dependent manner; therefore, TATP-OH was 
incubated for 10 min with recombinant enzymes (CYP and 
FMO) to determine which isoform is responsible for this 
secondary phase I metabolism (Table 3). Although TATP-
OH is not nearly as volatile as TATP, some TATP-OH was 
lost in all incubations (i.e., 37 ℃); however, notable deple-
tion (by 40%) was observed only with CYP2B6. TATP-OH 
depletion in CYP2B6 was faster in the presence of NADPH 
than in its absence, supporting metabolism by CYP2B6 (Fig. 
S9). Unfortunately, no subsequent metabolite was identified.
To identify which isoform is responsible for TATP glucu-
ronidation, TATP-OH was incubated with the most clinically 
relevant rUGTs (Fig. 5, Table S2) [40]. Glucuronidation was 
not observed with UGT1A1, UGT1A3, UGT1A4, UGT1A6 
and UGT1A9. TATP-O-glucuronide was formed only in 
UGT2B7 incubations with 0.05 ± 0.03 area count relative 
to IS produced after 2 h of incubation. HLM, which contains 
UGT2B7, also displayed TATP-O-glucuronide (0.26 ± 0.02 
area count relative to IS). Relative quantification of TATP-
O-glucuronide was done by area ratio to the IS because a 
TATP-O-glucuronide standard is not available. Endoper-
oxide glucuronidation by UGT2B7 has been reported, in 
which urine analysis of patients treated with artesunate, an 
Fig. 5  TATP-O-glucuronide formation from TATP-OH incubations 
with recombinant uridine diphosphoglucuronosyltransferase (rUGT). 
Experiments with rUGT consisted of 10  µg/mL TATP-OH incu-
bated with 10 mM phosphate buffer (pH 7.4), 2 mM  MgCl2, 50 µg/
mL alamethicin, 1 mM NADPH, and 5.5 mM uridine diphosphoglu-
curonic acid. Glucuronidation done in triplicate and quenched at 2 h. 
Quantification was done using area ratio TATP-O-glucuronide/inter-
nal standard 2,4-dichlorophenoxyacetic acid
Fig. 6  Rate of TATP hydroxylation by CYP2B6 versus TATP con-
centration. Incubations of various TATP concentrations consisted of 
50 pmol rCYP2B6/mL with 10 mM phosphate buffer (pH 7.4), 2 mM 
 MgCl2 and 1 mM NADPH. Incubations were done in triplicate and 
quenched every min up to 5 min
Fig. 7  Natural log of TATP-OH percent remaining in HLM versus 
time. TATP-OH (1  µM) incubated in 1  mg/mL HLM with preoxy-
genated 10 mM phosphate buffer (pH 7.4), 2 mM  MgCl2 and 1 mM 
NADPH. Incubations were done in closed vials, in triplicate and 
quenched every 10 min up to 1 h
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artemisinin derivative, found dihydroartemisinin-glucuron-
ide to be the principal metabolite excreted [16].
Enzyme kinetics
Rate of TATP hydroxylation by CYP2B6 was evaluated by 
plotting concentration of TATP-OH formed over time. The 
initial rate of TATP hydroxylation at various TATP con-
centrations was used to estimate enzyme kinetics using the 









Here, [S] is the substrate (TATP) concentration, Vmax is 
the maximum formation rate, Km is the substrate concen-
tration at half of Vmax, and kcat is the turnover rate of an 
enzyme–substrate complex to product and enzyme [41]. The 
kinetic constants were obtained using nonlinear regression 
analysis on GraphPad Prism software (version 8.2.1). The 
Michaelis–Menten evaluation for TATP hydroxylation by 
CYP2B6 (Fig. 6) yielded Km of 1.4 µM; Vmax of 8.7 nmol/
min/nmol CYP2B6; and kcat of 174 min− 1. Linearized mod-
els, such as Lineweaver–Burk (Fig. S10), Eadie–Hofstee 
(Fig. S11) and Hanes–Woolf (Fig. S12), give similar values.
The low Km indicates TATP has a high affinity for 
CYP2B6 [42]. Table 2 shows that TATP inhibits bupro-
pion hydroxylation by CYP2B6, with only 62% hydroxybu-
propion formation in 15 min. However, in the presence of 
bupropion, TATP-OH formation was enhanced, with 125% 
formed compared to the reaction uninhibited by bupropion 
(Table 2). CYP2B6 preference for TATP affects the metabo-
lism of bupropion, but further testing is needed to establish 
the specific type of inhibition.







 ) was calculated to be 6.13 mL/
min/nmol CYP2B6 [11, 43, 44]. Scale-up of the Clint to yield 
intrinsic clearance on a per kilogram body weight was done 
using values of 0.088 nmol CYP2B6/mg microsomal pro-
tein, 45 mg microsomal protein/g liver wet weight and 20 g 
liver wet weight/kg human body weight [43]. Taking that 
into account, the scale-up Clint was calculated to be 485 mL/
min/kg.
In vivo intrinsic clearance (Cl) is the ability of the 
liver to metabolize and remove a xenobiotic, assuming 
normal hepatic blood flow (Q = 21 mL/min/kg [43, 45]) 
and no protein binding [43]. Cl can be extrapolated using 
the well-stirred model excluding all protein binding as 




 [43]. The in vivo intrinsic clear-
ance of TATP was estimated as 20 mL/min/kg. Compared to 
common drugs, TATP has a moderate clearance [46].
TATP-OH kinetics were also investigated by substrate 
depletion. Substrate depletion was plotted as the natural 
log of substrate percent remaining over time (Fig. 7). Half-
life (t1/2) was calculated to be 16 min, as the natural log 
2 divided by the negative slope of the substrate depletion 
plot. In vitro intrinsic clearance (Clint) can also be estimated 
using half-life as Clint = (0.693/t1/2) × (incubation volume/mg 
microsomal protein) [47, 48]. The in vitro intrinsic clear-
ance of TATP-OH was estimated as 0.042 mL/min/mg. Even 
though we identified two metabolic pathways for TATP-OH, 
it appears to be cleared slower than TATP.
Lung metabolism
Inhalation is the most probable pathway for systemic expo-
sure since TATP is both volatile and lipophilic. With passive 
diffusion into the bloodstream being very possible, TATP 
metabolism in the lung was also investigated. TATP was 
incubated in lung and liver microsomes for comparison of 
metabolic rate. The results, shown in Table 4, indicated that 
TATP hydroxylation in the lungs was negligible. Though 
CYP2B6 gene and protein are expressed in the lungs, 
enzyme activity in lungs is minimal as compared to the liver, 
limiting TATP metabolism [49, 50]. This suggests that TATP 
is most likely distributed through the blood to the liver for 
metabolism. News reported that traces of TATP was found in 
the blood samples extracted from the 2016 Brussels suicide 
bombers [51]. This indicates the possibility of using blood 
tests as forensic evidence for TATP exposure.
In vivo human urine analysis
Laboratory workers, who normally work with TATP on a 
daily basis, performing tasks like explosive sensitivity test-
ing, were screened for TATP exposure. These laboratory 
workers volunteered to collect their urine before and after 
exposure to TATP vapor. Since the health effects of TATP 
exposure are unknown, to minimize any additional risks to 
these workers, this pilot study was performed in duplicates 
using only three volunteers to establish some reproducibil-
ity. TATP and TATP-OH were not observed in the urine of 
any of the workers. However, TATP-O-glucuronide was pre-
sent in all urine samples collected 2 h after TATP exposure 
(Fig. 8). Two out of the three volunteers still showed TATP-
O-glucuronide in the urine collected the next day (Table 5). 
TATP-O-glucuronide was identified in human urine samples 
as both [TATP-O-glucuronide −  H]− and [TATP-O-glucuro-
nide + NH4]+. The presence of TATP-O-glucuronide in the 
urine of all three volunteers is summarized in Table 5.
Table 4  Rate of TATP hydroxylation (triplicates) in human liver 
microsomes versus human lung microsomes
< LOQ lower than the limit of quantification
Human microsomes Rate of TATP-OH 
formation (nmol/min/
mg)
Liver 0.425 ± 0.06
Lung lot1710142  < LOQ




As described before, TATP is the explosive of choice by 
terrorists because it is easily synthesized from household 
items [1, 2]. In our previous study, we have clarified that 
TATP-OH is produced as an in vitro metabolite from TATP 
in dogs [15], because canines are currently one of the most 
reliable detection techniques used to find an explosive 
[52]. In the present article, the study has been conducted 
in continuation of our previous findings on both in vitro 
and in vivo metabolism of TATP in humans (Fig. 2).
Because TATP has high volatility, it is likely to be 
absorbed into the body by inhalation; however, no 
appreciable metabolism in the lung was observed in either 
dog [15] or human microsomes (Table 4). Therefore, sys-
temic exposure and subsequent liver metabolic clearance 
were presumed. Across three species, dog, rat, and human, 
TATP was metabolized in liver microsomes by CYP to 
TATP-OH (Fig. S5). Using recombinant enzymes, we 
have previously established that CYP2B11 is responsible 
for this metabolism in dogs [15]. Interestingly, human 
CYP2B6 appears to be the major phase I enzyme respon-
sible for the same metabolism (Fig. 4). TATP hydroxy-
lation by CYP2B6 kinetics determined Km and Vmax as 
1.4 µM and 8.7 nmol/min/nmol CYP2B6, respectively 
(Fig. 6). Though heat inactivation and chemical inhibition 
of FMO appeared to affect TATP hydroxylation (Table 2), 
Fig. 8  Extracted ion chromatogram of [TATP-O-glucuronide −  H]− (m/z 413.1301) in HLM 2  h after incubation with TATP, and in human 
urine, before TATP exposure and 2 h after TATP exposure
Table 5  Summary of TATP-O-
glucuronide presence in human 
urine (duplicates) in vivo
TATP glucuronide is observed as [TATP-O-glucuronide −  H]− (m/z 413.1301) and [TATP-O-glucuron-
ide + NH4]+ (m/z 432.1712, less sensitive). Only one trial performed on next day samples
Human m/z 413.1301 m/z 432.1712
#1 #2 #3 #1 #2 #3
Before TATP exposure − − − − − −
Two hours after TATP exposure  +  +  +  +  +  + 
One day after TATP exposure  +  + −  + − −
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incubations with recombinant FMO suggest that FMO was 
not forming TATP-OH (Fig. 4). Methimazole, an FMO 
inhibitor, inhibited TATP-OH formation (Table 2); but, 
inhibition of bupropion by this chemical inhibitor suggests 
that methimazole also inhibits CYP2B6 activity [39].
When incubated together, TATP and bupropion appear to 
compete for CYP2B6 metabolism, with bupropion hydrox-
ylation being inhibited by 38% in the presence of TATP 
(Table 2). Considering CYP2B6 expression in the liver is 
low and exhibits broad genetic polymorphisms, CYP2B6 
activity can be widely affected if TATP affects the metabo-
lism of other compounds, like bupropion [53, 54]. TATP 
may be a serious perpetrator for drug-drug interactions for 
compounds cleared by CYP2B6 [55, 56].
In vitro clearance of TATP was calculated as 0.54 mL/
min/mg protein with hepatic in  vivo extrapolation to 
20 mL/min/kg. In vitro clearance of TATP-OH was esti-
mated, using substrate depletion, as 0.038 mL/min/mg pro-
tein (Fig. 7). We also established the clearance of TATP 
in dogs as 0.36 mL/min/mg protein in our previous study 
in canine microsomes [15], which is significantly relevant 
to K9 units, where the dog and human handler are both 
exposed to the explosive.
Investigation into the next step on the metabolic path-
way suggested that TATP-OH is further metabolized by 
CYP2B6 (Table 3), but a secondary phase I metabolite 
was not identified. No glutathione adducts of any TATP 
metabolism products were observed in the microsomal 
incubations with GSH (Fig. S6). However, glucuroni-
dation converted TATP-OH to TATP-O-glucuronide in 
HLM with UGT2B7 specifically catalyzing this reaction 
(Fig. 5). Considering glucuronides are often observed as 
urinary metabolites, the presence of TATP-O-glucuronide 
in urine can be exploited as an absolute marker of expo-
sure to TATP, which can be used as forensic evidence of 
TATP illegal use.
Urine from scientists working to prevent terrorist attacks 
by synthesizing, characterizing and detecting TATP, who 
are inevitably exposed to this volatile compound were nega-
tively tested for TATP and TATP-OH, but TATP-O-glucuro-
nide was present at high levels in their fresh urine (Fig. 8). 
In one out of the three volunteers, TATP-O-glucuronide was 
not observed in the urine collected the day after TATP expo-
sure (Table 5), suggesting TATP to TATP-O-glucuronide 
in vivo clearance occurs within about a day depending on the 
exposure level. TATP-O-glucuronide presence in the urine 
of all three volunteers shows good in vivo correlation to 
in vitro data.
Like TATP (hydrophilicity expressed as TPSA = 55.38 
and lipophilicity expressed as cLogP = 3.01, calculated using 
PerkinElmer ChemDraw Professional version 16.0.1.4), 
TATP-OH is lipophilic with TPSA and cLogP of 75.61 and 
1.72, respectively. TATP-O-glucuronide, on the other hand, 
is hydrophilic with TPSA and cLogP of 171.83 and 0.32, 
respectively. The increase in TPSA and decrease in cLogP 
from TATP to TATP-O-glucuronide accounts for the glucu-
ronide greater water solubility and facilitated excretion [11], 
thus explaining the presence of only TATP-O-glucuronide 
in urine.
Even though working with TATP falls under the protec-
tion of several standard operating procedures to handling 
explosives, considering the breathing exposure that these 
laboratory workers revealed, implementation of precaution-
ary measures to absorption by inhalation, such as the use of 
respirators, should be considered. Such detection of TATP-
O-glucuronide is also useful for judicial authorities to raise 
a scientific evidence for exposure to TATP of terrorists and/
or related individuals.
This paper is the first to examine some aspects of TATP 
human ADMET, elucidating the exposure, metabolism and 
excretion of TATP in humans. However, the detailed phar-
macological and toxicological studies remain to be explored.
Conclusions
This article dealt with in vitro and in vivo studies of TATP 
metabolism in humans. TATP is highly volatile and easily 
introduced into human body via aspiration. By this study, 
TATP was found to be metabolized into TATP-OH by the 
action of CYP2B6, followed by glucuronidation of TATP-
OH catalyzed by UGT2B7; the resulting TATP-O-glucuro-
nide was found to be excreted into urine in live humans. 
After extracting the TATP conjugate from urine specimens, 
it can be analyzed by HPLC–MS/MS, which gives scien-
tific evidence for exposure to TATP. This evidence can be 
useful to prove exposure of persons, such as terrorists, to 
TATP for judicial authorities. Although this study includes 
the metabolism of TATP and also an analytical method to 
detect the TATP-O-glucuronide, the toxicology of TATP 
remains to be explored.
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